Navigation Links
Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
Date:3/31/2008

HOPKINTON, Mass., March 31 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that the report of the Company's independent registered public accounting firm regarding the Company's 2007 financial statements contained an explanatory paragraph regarding the Company's ability to continue as a going concern. NASDAQ Marketplace Rules require NASDAQ-traded companies to publicly announce if their Annual Report on Form 10-K includes an audit report containing a going concern explanatory paragraph. For further information, please refer to the Company's Annual Report on Form 10-K filed on March 31, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. CETHRIN(R), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potential
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Alseres Pharmaceuticals, Inc. Raises $5 Million
2. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
3. Barr Pharmaceuticals, Inc. Executive Bios
4. Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
5. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
6. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
7. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
8. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
9. Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008
10. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
11. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Texas (PRWEB) July 14, 2014 The ... encourage investment in the Global Mobile Health Solutions market. ... in the Health IT for Economic and Clinical Health ... February 2009. , Analysts forecast the Global Mobile ... of 34.88 percent over the period 2013-2018. According to ...
(Date:7/14/2014)... The report “Intelligent Building Automation Technologies ... Safety, Facility Management], IT Technologies & Industry Verticals ... - 2019)” defines and segments the IBAS market ... forecasting of revenues. The report also identifies the ... impacting it, along with the technology roadmap and ...
(Date:7/14/2014)... Physical fitness may buffer some of the adverse health ... study by researchers from the American Cancer Society, The ... appears in the journal Mayo Clinic Proceeding s, ... obesity and blood markers associated with cardiovascular disease is ... Sedentary behavior has been linked to an increase risk ...
(Date:7/14/2014)... TX (PRWEB) July 14, 2014 ... heart valves market in Americas. The analysis includes ... the 2007–2020 period and key company share data ... US, Canada, Brazil and Mexico. It uses data ... secondary research and in-house analysis. , Scope, ...
(Date:7/14/2014)... Secure Decisions, a leading provider of ... the Software Assurance Marketplace (SWAMP) to build a powerful ... drives everyday life. , The SWAMP, implemented by a ... Morgridge Institute for Research, is funded by the Department ... practices by building a free facility with a diverse ...
Breaking Medicine News(10 mins):Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 2Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 3Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 4Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 3Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 4Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3
... made him the last of his line, researchers say ... powerful Habsburg royal family ruled Spain for centuries until the ... , Now, a new study suggests the reason for their ... and their unfortunate habit of marrying their own relatives. ...
... the highest level of excellence, achieving ASQ CQI Certifications. , ... ... Board of the American Society for Quality is pleased to announce ... completed the requirements to be named an ASQ-Certified Quality Inspector (ASQ ...
... 8 Saints Mary and Elizabeth Medical Center, 2233 ... Blue Cross and Blue Shield of Illinois, Childhood Health ... for children at risk for obesity and diabetes. This ... Obesity is an epidemic in the United States. Since ...
... 8 This Sunday, individuals all over the ... the women who gave them life: their mothers. While people ... the International Breast Milk Project (IBMP) hopes to inspire some ... organization that helps mothers in the United States send their ...
... Protect Patients and Consumers ROCKVILLE, Md., May 8 ... substantial increase in funding for the Food and ... budget. Following the Obama administration,s voiced support for ... increase the agency,s ability to protect American patients ...
... May 8 PRO-DEX, INC. (Nasdaq: PDEX ) ... of the Company,s fiscal 2009 third quarter financial results. The ... on Thursday, May 14, 2009 at 4:30 p.m. Eastern Time ... Company,s website at www.pro-dex.com . Mark ...
Cached Medicine News:Health News:Inbreeding May Have Doomed Spain's Habsburg Dynasty 2Health News:Inbreeding May Have Doomed Spain's Habsburg Dynasty 3Health News:Clinical Instrument Repair Consultants Receive ASQ-Certified Quality Inspector 2Health News:Blue Cross and Blue Shield Funds Diabetes Education at Saints Mary and Elizabeth Medical Center 2Health News:International Breast Milk Project Helps Mothers Worldwide 2Health News:USP Applauds President's Budget Support for FDA 2Health News:Pro-Dex, Inc. Announces Fiscal 2009 Third Quarter Financial Results Conference Call and Webcast 2
(Date:7/14/2014)... 14, 2014  Mylan Inc. (NASDAQ: MYL ) ... with Abbott (NYSE: ABT ... non-U.S. developed markets specialty and branded generics business ("the Assets") ... will receive 105 million shares of the combined company ... $50.20 on Friday, July 11, 2014, representing an approximately 21% ...
(Date:7/13/2014)... July 13, 2014  Eli Lilly and Company ... from its non-clinical study in genetically engineered mice ... the beta-amyloid antibody N3pG and beta-secretase inhibitor BACE ... more effective in removing clumps of amyloid-beta protein ... thought to lead to Alzheimer,s disease (AD) – ...
(Date:7/11/2014)... , July 11, 2014 The consumer ... evolving across industry sectors to better identify winning ... ways to engage with and understand consumers, as ... and make critical purchasing decisions. ... Practices, LLC, one area where organizations can observe ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Technologies Transforming Consumer Marketing Research Playbook 2